Liquet Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Liquet Medical is an early-stage medical device innovator developing the Versus Catheter, a novel pulmonary artery drug delivery system. Its first-in-class device features a dual-tip design for simultaneous bilateral lung treatment, flow-directed balloon placement, and real-time pressure monitoring to optimize therapy. The company is pre-revenue and privately held, aiming to address a significant unmet need in interventional cardiology and pulmonology through localized, efficient drug administration.

Pulmonary Vascular Disease

Technology Platform

The Versus Catheter, a pulmonary artery drug delivery platform featuring a patent-protected dual-tip design for bilateral treatment, a flow-directed balloon for placement, and integrated real-time pressure monitoring to optimize therapy.

Opportunities

The Versus Catheter addresses a clear need for more efficient and controlled localized drug delivery in the pulmonary vasculature, a challenging anatomical target.

Its ability to treat both lungs simultaneously could reduce procedure time and cost, while real-time monitoring may improve therapeutic precision and outcomes, creating a strong value proposition for hospitals.

Risk Factors

As an early-stage, pre-revenue company with a novel, unproven device, Liquet faces significant technical, regulatory, and commercialization risks.

It must demonstrate clinical safety/efficacy, navigate a potentially complex FDA pathway, and compete against large, entrenched players in the vascular access market with limited resources.

Competitive Landscape

Liquet competes in the broad catheter-based drug delivery market dominated by large medical device companies (e.g., Boston Scientific, Medtronic). Its direct competitors are other specialized infusion catheters, but its dual-tip design and flow-directed placement for bilateral pulmonary treatment represent a unique, niche differentiation if successfully developed.

More companies in United States →